I-Exact Sciences Corp. namhlanje ibhengeze ukuba idatha evela kwi-Rx ye-Positive Node, i-Endocrine Responsive Breast Cancer, okanye i-RxPONDER, ilingo lipapashwe kwi-New England Journal of Medicine.i Uphononongo, olukhokelwa yi-SWOG Cancer Research Network ezimeleyo kwaye ixhaswe ngu I-National Cancer Institute (NCI), ichaze ngempumelelo inzuzo ye-chemotherapy kwinqanaba lokuqala, izigulane zomhlaza wesifuba ze-node-positive kunye ne-Oncotype DX Breast Recurrence Score® iziphumo ze-0 ukuya kwi-25. Iziphumo zokuqala ezivela kwi-RxPONDER zichazwe kwi-2020 ye-San Antonio Breast Cancer. I-Symposium (SABCS). Okufunyenweyo ngoku kuqinisekisiwe kolu papasho luphononongwe ngoontanga.
Okubalulekileyo, akukho nzuzo ye-chemotherapy yabonwa kungakhathaliseki inani leendawo ezichaphazelekayo, ibakala le-tumor okanye ubungakanani. Kwabasetyhini be-premenopausal abane-1 ukuya kwi-3 i-node ezintle, inzuzo ye-chemotherapy ephawulekayo yabonwa.
Malunga nesinye kwisithathu sezigulana ezifunyaniswe zine-hormone receptor (HR)-positive, i-HER2-negative ekuqaleni umhlaza wamabele zinethumba elithe lanwenwela kwii-lymph nodes. Uninzi lwezi zigulana ngoku zifumana ichemotherapyii nangona malunga ne-85% yazo ineziphumo zokuPhinda kokuPhinda kuka-0 ukuya kuma-25.
Ngokusekwe kwiziphumo ze-RxPONDER, iNational Comprehensive Cancer Network® (NCCN®)v ihlaziye izikhokelo zayo zomhlaza wamabele kwaye yaqaphela uvavanyo lwe-Oncotype DX Breast Recurrence Score njengovavanyo kuphela olunokuthi lusetyenziswe ukuqikelela inzuzo yechemotherapy ekuqaleni kwebele. izigulane zomhlaza kunye ne-1 ukuya kwi-3 ye-axillary lymph nodes e-positive, kuquka i-micrometastases.vi Uvavanyo lwe-Oncotype DX ngoku kuphela kovavanyo oluchazwe "njengolukhethwayo" olunobungqina obuphezulu bobungqina be-node-negative kunye ne-postmenopausal node-positive (1 ukuya kwi-3 i-positive nodes ) izigulane. Ukongeza, i-NCCN incoma ukuqwalasela uvavanyo lokuvavanya i-prognosis kwizigulane ze-premenopausal node-positive ezingabaviwa be-chemotherapy.
Olona vavanyo lukhulu lwezonyango kwi-node-positive, i-HR-positive, i-HER2-negative ekuqaleni komhlaza wamabele, i-RxPONDER ibhalise ngaphezu kwama-5,000 abasetyhini kunye neendawo ezintathu ezilungileyo. Uphononongo olulindelekileyo, olungenamkhethe lweSigaba sesi-III lwaqhutywa kwiindawo ezingama-632 kumazwe alithoba - eUnited States, eCanada, eMexico, eKholombiya, e-Ireland, eFransi, eSpain, eMzantsi Korea naseSaudi Arabia. Abasetyhini abanesiphumo sokuPhinda kwakhona kwesiphumo se-0 ukuya kwi-25 benziwe ngokungakhethiyo kunyango ngonyango lwehomoni yodwa okanye ichemotherapy elandelwa lunyango lwehomoni. Izigulane ezihleliweyo zahlulwe ngokusekwe kwisiphumo seNqaku lokuPhinda, imeko ye-menopausal kunye nohlobo lotyando lwe-lymph node. Uhlalutyo olongezelelweyo kunye nokulandelela isigulane esongezelelweyo kucwangciswe ngabaphandi be-SWOG.
INTO ONOKUYITHATHA KWELI NQAKU:
- Based on the RxPONDER results, the National Comprehensive Cancer Network® (NCCN®)v updated its guidelines for breast cancer and recognized the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1 to 3 positive axillary lymph nodes, including micrometastases.
- I The study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25.
- Women with a Recurrence Score result of 0 to 25 were randomized to treatment with hormone therapy alone or chemotherapy followed by hormone therapy.
